Adocia to Present AdoShell and BioChaperone Data at EASD 2026
The Lyon-based biopharmaceutical company announced its participation in two international scientific congresses, where data on its AdoShell cell encapsulation platform and full results from a phase 3 study of BioChaperone Lispro conducted in China will be presented.
These communications follow the decision made in the first quarter of 2026 to prioritize the development of BioChaperone technology.
Two Congresses and Three Oral Presentations Scheduled
Adocia indicated that data relating to scaling up the AdoShell platform for human application will be the subject of two oral presentations at the 2026 annual congress of the European Association for the Study of Diabetes (EASD) and the first Breakthrough T1D Clinical & Research congress.
The EASD congress will be held from September 28 to October 2, 2026 in Milan, Italy, while the Breakthrough T1D congress will take place from October 9 to 11, 2026 in Philadelphia, United States.
Furthermore, the full results of the phase 3 clinical study of BioChaperone Lispro in people with type 2 diabetes in China will be presented at the EASD congress, during a session dedicated to developments in new insulins.
AdoShell Clinical Trial Application Suspended in Favor of BioChaperone
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Adocia recalled that during the first quarter of 2026, it decided to prioritize the development of its BioChaperone technology and suspend activities related to the submission of the clinical trial application for AdoShell with human pancreatic islets, originally planned for the third quarter of 2026.
According to the Company, this clinical objective could be resumed as soon as the financial situation and human resources allow.
BioChaperone Lispro, an ultra-rapid insulin, was licensed to Tonghua Dongbao in 2018 as part of a licensing agreement covering China and other Asian countries. Based in Lyon, Adocia has approximately 80 employees and has a portfolio of drug candidates derived from four proprietary technology platforms.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
